GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » Gross-Profit-to-Asset %

Innovative Pharmaceutical Biotech (HKSE:00399) Gross-Profit-to-Asset % : 0.04% (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Innovative Pharmaceutical Biotech's annualized Gross Profit for the quarter that ended in Sep. 2024 was HK$0.61 Mil. Innovative Pharmaceutical Biotech's average Total Assets over the quarter that ended in Sep. 2024 was HK$1,380.94 Mil. Therefore, Innovative Pharmaceutical Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 0.04%.


Innovative Pharmaceutical Biotech Gross-Profit-to-Asset % Historical Data

The historical data trend for Innovative Pharmaceutical Biotech's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative Pharmaceutical Biotech Gross-Profit-to-Asset % Chart

Innovative Pharmaceutical Biotech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.10 0.08 0.06 0.06

Innovative Pharmaceutical Biotech Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.05 0.07 0.04

Competitive Comparison of Innovative Pharmaceutical Biotech's Gross-Profit-to-Asset %

For the Specialty Retail subindustry, Innovative Pharmaceutical Biotech's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovative Pharmaceutical Biotech's Gross-Profit-to-Asset % Distribution in the Retail - Cyclical Industry

For the Retail - Cyclical industry and Consumer Cyclical sector, Innovative Pharmaceutical Biotech's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Innovative Pharmaceutical Biotech's Gross-Profit-to-Asset % falls into.


;
;

Innovative Pharmaceutical Biotech Gross-Profit-to-Asset % Calculation

Innovative Pharmaceutical Biotech's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=0.84/( (1384.048+1383.023)/ 2 )
=0.84/1383.5355
=0.06 %

Innovative Pharmaceutical Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0.614/( (1383.023+1378.866)/ 2 )
=0.614/1380.9445
=0.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Innovative Pharmaceutical Biotech Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovative Pharmaceutical Biotech Business Description

Traded in Other Exchanges
N/A
Address
145 Hennessy Road, Unit No. 2002, 20th Floor, On Hong Commercial Building, Wan Chai, Hong Kong, HKG
Innovative Pharmaceutical Biotech Ltd is a Hong Kong-based investment holding company principally engaged in pharmaceuticals and biotechnology businesses. The company has two operating segments; Trading of beauty products in Hong Kong and Research, development, and commercialisation of the oral insulin product. The company generates almost all of its revenue from Hong Kong.
Executives
Chau Yiu Ting 2101 Beneficial owner
Mao Yumin 2101 Beneficial owner
Extrawell Pharmaceutical Holdings Limited
Mao Yumin 2101 Beneficial owner
Chau Yiu Ting 2101 Beneficial owner

Innovative Pharmaceutical Biotech Headlines

No Headlines